| Followers | 236 |
| Posts | 10817 |
| Boards Moderated | 0 |
| Alias Born | 07/17/2006 |
Monday, August 17, 2015 10:59:08 PM
raf...
You need to read my post carefully. There are two separate situations here..1) Watson petitions the court to appeal the NCE decision, because the FDA has declined to do so. 2) a second scenario occurs if Watson is allowed to appeal the NCE decision, then what are the consequences of then winning or losing the appeal.
My contention is that Watson wants to appeal the NCE decision for the same reason the FDA does not want to appeal the NCE decision, because both Watson and the FDA know the chances of winning the appeal are very close to zero. The reason the appeal is such a loser is related to the FDA's almost criminal behavior in handling the NCE decision..For example changing congressional statutes. So FDA does not wish to appeal the decision because they know they will lose and this will further diminish the FDA and set a precedent.. Watson on the other wants to appeal the decision also knowing the appeal is a loser. They are doing this, because a losing appeal decision which they anticipate will be based on FDA's bad behavior and will tarnish the FDA which is Watson's strategy. Watson is doing the force a losing appeal decision on the FDA.
My posts are not about Watson winning the appeal decision.
"JL, were you saying that FDA opposed Watson's appeal because if Watson won and AMRN appealed, that would go to supreme court?"
No No No No!!! Watson wants to appeal the decision, because they know they will lose the appeal decision and that will reflect (bring more attention to) the shoddy way the FDA does business. Right now the out of control FDA is bad for the drug industry and this is a good way to strike back at the FDA.
":>) JL
You need to read my post carefully. There are two separate situations here..1) Watson petitions the court to appeal the NCE decision, because the FDA has declined to do so. 2) a second scenario occurs if Watson is allowed to appeal the NCE decision, then what are the consequences of then winning or losing the appeal.
My contention is that Watson wants to appeal the NCE decision for the same reason the FDA does not want to appeal the NCE decision, because both Watson and the FDA know the chances of winning the appeal are very close to zero. The reason the appeal is such a loser is related to the FDA's almost criminal behavior in handling the NCE decision..For example changing congressional statutes. So FDA does not wish to appeal the decision because they know they will lose and this will further diminish the FDA and set a precedent.. Watson on the other wants to appeal the decision also knowing the appeal is a loser. They are doing this, because a losing appeal decision which they anticipate will be based on FDA's bad behavior and will tarnish the FDA which is Watson's strategy. Watson is doing the force a losing appeal decision on the FDA.
My posts are not about Watson winning the appeal decision.
"JL, were you saying that FDA opposed Watson's appeal because if Watson won and AMRN appealed, that would go to supreme court?"
No No No No!!! Watson wants to appeal the decision, because they know they will lose the appeal decision and that will reflect (bring more attention to) the shoddy way the FDA does business. Right now the out of control FDA is bad for the drug industry and this is a good way to strike back at the FDA.
":>) JL
Recent AMRN News
- Amarin to Report First Quarter 2026 Financial Results and Host Conference Call on April 29, 2026 • GlobeNewswire Inc. • 04/15/2026 12:00:00 PM
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 04/10/2026 09:01:34 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 04/10/2026 09:00:20 PM
- American College of Cardiology (ACC) Scientific Sessions 2026 Underscore the Need for Complementary Therapies Including Icosapent Ethyl (IPE) in Treatment of Elevated Triglycerides and Cardiovascular Risk Reduction • GlobeNewswire Inc. • 04/08/2026 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/02/2026 08:30:11 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 03/30/2026 09:57:06 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/27/2026 09:00:07 PM
- Amarin Highlights Guideline Recommended Role of Icosapent Ethyl in Managing Cardiovascular Risk Following Release of Updated 2026 ACC/AHA/Multisociety Dyslipidemia Guideline • GlobeNewswire Inc. • 03/18/2026 12:30:00 PM
- New REDUCE-IT Data in Patients at Extreme Cardiovascular Risk and In Vitro Research on the Mechanistic Effects of Eicosapentaenoic Acid (EPA) on Lipoprotein(a) [Lp(a)] Oxidation to be Presented at the American College of Cardiology’s (ACC) Annual Scienti • GlobeNewswire Inc. • 03/16/2026 12:15:00 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/02/2026 10:31:01 PM
- Effects of Icosapent Ethyl on Risk and Duration of Hospitalizations and Death in REDUCE-IT® Post Hoc Analysis Published in the European Journal of Preventive Cardiology • GlobeNewswire Inc. • 03/02/2026 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/25/2026 12:05:26 PM
- Amarin Reports Fourth Quarter and Full Year 2025 Financial Results • GlobeNewswire Inc. • 02/25/2026 12:00:00 PM
- This American Heart Month Amarin Spotlights the Need to Prioritize Proven Widely Available Yet Underutilized Therapies in the Battle Against Cardiovascular Disease • GlobeNewswire Inc. • 02/23/2026 01:00:00 PM
- Amarin to Report Fourth Quarter and Full Year 2025 Financial Results and Host Conference Call on February 25, 2026 • GlobeNewswire Inc. • 02/11/2026 01:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/04/2026 12:00:09 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/04/2026 12:00:07 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/04/2026 12:00:06 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/04/2026 12:00:05 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/04/2026 12:00:04 AM
- Amarin Applauds Breakthroughs In Therapies For Patients With Elevated Triglycerides; Company’s VASCEPA®/VAZKEPA® (Icosapent Ethyl) Franchise Well Positioned To Benefit Globally From Broadened Category Commercialization • GlobeNewswire Inc. • 01/09/2026 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/08/2026 12:05:27 PM
- Amarin Announces Preliminary 2025 Financial Highlights and Operational Accomplishments, Including Achieving Positive Cash Flow; Company Well Positioned to Capture Global Growth Opportunities • GlobeNewswire Inc. • 01/08/2026 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/06/2026 10:00:21 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/06/2026 10:00:17 PM
